Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Authors:
- Ramsay HaferRHRamsay Hafer
- Francesco IadevaiaFIFrancesco Iadevaia
- Thomas Z. RohanTRThomas Z. Rohan
- Teresa DuongTDTeresa Duong
- Maria PoluchMPMaria Poluch
- Gina KeifferGKGina Keiffer
- Michael LiMLMichael Li
- Andres FerberAFAndres Ferber
- Luca LaurentiLLLuca Laurenti
- Alan S. KhooAKAlan S. Khoo
- Pierluigi PorcuPPPierluigi Porcu
Open Access
- 28 December 2024
- journal article
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (1)
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trialBlood, 2023
- A global federated real-world data and analytics platform for researchJAMIA Open, 2023
- Diagnosis and Treatment of Chronic Lymphocytic LeukemiaJAMA, 2023
- Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaBlood Advances, 2022
- Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaLeukemia, 2022
- Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 resultsBlood, 2020
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2016
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2015
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaJAMA Oncology, 2015
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2014